Abstract
We analyzed the clinical efficacy and safety of chemotherapy using S-1 plus weekly CDDP( w-CS therapy) for unresectable gastric cancer. Twenty one patients were treated with this treatment. S-1 80 mg/m2/day was administered for 2 weeks followed by a 1-week rest. CDDP 20 mg/m2 was injected intravenously on day 1 and 8. The overall response rate was 52. 3%. The disease control rate was 85.7%. Grade 3 or 4 major toxicity comprised neutropenia (14.2%), thrombocytopenia (4.7%) and plasma creatinine elevation (4.7%). w-CS therapy is satisfied resulting with efficacy and safety. Thus, future clinical trials and accumulation of futher cases are warranted.
| Original language | English |
|---|---|
| Pages (from-to) | 2351-2353 |
| Number of pages | 3 |
| Journal | Gan to kagaku ryoho. Cancer & chemotherapy |
| Volume | 38 |
| Issue number | 12 |
| Publication status | Published - 2011 Jan 1 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
[Treatment of S-1 plus weekly CDDP for advanced gastric cancer]. / Kemmochi, Takeshi; Egawa, Tomohisa; Mihara, Yasunori; Irino, Tomoyuki; Ito, Yasuhiro; Nagashima, Atsushi; Makino, Hiroyuki; Yamamuro, Wataru.
In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 38, No. 12, 01.01.2011, p. 2351-2353.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - [Treatment of S-1 plus weekly CDDP for advanced gastric cancer].
AU - Kemmochi, Takeshi
AU - Egawa, Tomohisa
AU - Mihara, Yasunori
AU - Irino, Tomoyuki
AU - Ito, Yasuhiro
AU - Nagashima, Atsushi
AU - Makino, Hiroyuki
AU - Yamamuro, Wataru
PY - 2011/1/1
Y1 - 2011/1/1
N2 - We analyzed the clinical efficacy and safety of chemotherapy using S-1 plus weekly CDDP( w-CS therapy) for unresectable gastric cancer. Twenty one patients were treated with this treatment. S-1 80 mg/m2/day was administered for 2 weeks followed by a 1-week rest. CDDP 20 mg/m2 was injected intravenously on day 1 and 8. The overall response rate was 52. 3%. The disease control rate was 85.7%. Grade 3 or 4 major toxicity comprised neutropenia (14.2%), thrombocytopenia (4.7%) and plasma creatinine elevation (4.7%). w-CS therapy is satisfied resulting with efficacy and safety. Thus, future clinical trials and accumulation of futher cases are warranted.
AB - We analyzed the clinical efficacy and safety of chemotherapy using S-1 plus weekly CDDP( w-CS therapy) for unresectable gastric cancer. Twenty one patients were treated with this treatment. S-1 80 mg/m2/day was administered for 2 weeks followed by a 1-week rest. CDDP 20 mg/m2 was injected intravenously on day 1 and 8. The overall response rate was 52. 3%. The disease control rate was 85.7%. Grade 3 or 4 major toxicity comprised neutropenia (14.2%), thrombocytopenia (4.7%) and plasma creatinine elevation (4.7%). w-CS therapy is satisfied resulting with efficacy and safety. Thus, future clinical trials and accumulation of futher cases are warranted.
UR - http://www.scopus.com/inward/record.url?scp=84858830425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858830425&partnerID=8YFLogxK
M3 - Article
C2 - 22202379
AN - SCOPUS:84858830425
VL - 38
SP - 2351
EP - 2353
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 12
ER -